Comparative Pharmacology
Head-to-head clinical analysis: ASACOL HD versus SFROWASA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASACOL HD versus SFROWASA.
ASACOL HD vs SFROWASA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mesalamine, the active ingredient, is a 5-aminosalicylic acid (5-ASA) derivative that acts locally in the colon to reduce inflammation by inhibiting prostaglandin production and leukotriene synthesis, likely through scavenging free radicals and blocking cytokine release.
SFROWASA is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
2 tablets (1600 mg) once daily with or without food.
5-aminosalicylic acid (mesalamine) 1 g orally 4 times daily for acute treatment; maintenance 500 mg orally 3 times daily.
None Documented
None Documented
Terminal elimination half-life is 5-10 hours for 5-ASA and 5-10 hours for acetyl-5-ASA; clinically, it supports twice-daily dosing.
Terminal elimination half-life: 12-14 hours in healthy adults; prolonged in hepatic impairment (up to 24 hours) or severe renal disease (up to 20 hours).
Primarily renal excretion of acetyl-5-ASA (about 80% of absorbed dose) and unchanged 5-ASA; minor fecal elimination (<20%).
Renal: 80% as unchanged drug; biliary/fecal: <15% as metabolites; minor hepatic metabolism via CYP3A4.
Category C
Category C
Aminosalicylate
Aminosalicylate